Effect of co-processed excipient type on properties of orodispersible tablets containing captopril, tramadol, and domperidone
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22340%2F23%3A43926406" target="_blank" >RIV/60461373:22340/23:43926406 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/62690094:18470/23:50020375 RIV/00216208:11160/23:10470678
Výsledek na webu
<a href="https://doi.org/10.1016/j.ijpharm.2023.122838" target="_blank" >https://doi.org/10.1016/j.ijpharm.2023.122838</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ijpharm.2023.122838" target="_blank" >10.1016/j.ijpharm.2023.122838</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Effect of co-processed excipient type on properties of orodispersible tablets containing captopril, tramadol, and domperidone
Popis výsledku v původním jazyce
An important feature of orodispersible tablets (ODTs) is the convenient administration of the drugs, in some cases, faster onset of action, stability maintenance, and dose precision. This work focused on the preparation of ODTs containing mannitol-based co-processed excipients Prosolv® ODT G2, Ludiflash® and Parteck® ODT in combination with tramadol, captopril, and domperidone by direct compression. Prosolv® ODT G2 showed high energy of plastic deformation due to the content of microcrystalline cellulose. Parteck® ODT provided compact tablets due to the content of granulated mannitol. All drugs decreased tensile strength, increased friability, prolonged disintegration time, and decreased the porosity of tablets. Tablets containing Prosolv® ODT G2 with captopril, domperidone, and tramadol; and Parteck® ODT with domperidone met the requirements for ODTs production, i.e., friability ≤ 1% and disintegration time ≤ 180 s, fast wetting time, high water absorption ratio, and adequate tensile strength. The disintegration time was tested using both the pharmacopeial method and the BJKSN-13 apparatus. The results indicate the significant difference between these methods, with the disintegration time being longer when tested with the BJKSN-13 instrument. © 2023 Elsevier B.V.
Název v anglickém jazyce
Effect of co-processed excipient type on properties of orodispersible tablets containing captopril, tramadol, and domperidone
Popis výsledku anglicky
An important feature of orodispersible tablets (ODTs) is the convenient administration of the drugs, in some cases, faster onset of action, stability maintenance, and dose precision. This work focused on the preparation of ODTs containing mannitol-based co-processed excipients Prosolv® ODT G2, Ludiflash® and Parteck® ODT in combination with tramadol, captopril, and domperidone by direct compression. Prosolv® ODT G2 showed high energy of plastic deformation due to the content of microcrystalline cellulose. Parteck® ODT provided compact tablets due to the content of granulated mannitol. All drugs decreased tensile strength, increased friability, prolonged disintegration time, and decreased the porosity of tablets. Tablets containing Prosolv® ODT G2 with captopril, domperidone, and tramadol; and Parteck® ODT with domperidone met the requirements for ODTs production, i.e., friability ≤ 1% and disintegration time ≤ 180 s, fast wetting time, high water absorption ratio, and adequate tensile strength. The disintegration time was tested using both the pharmacopeial method and the BJKSN-13 apparatus. The results indicate the significant difference between these methods, with the disintegration time being longer when tested with the BJKSN-13 instrument. © 2023 Elsevier B.V.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
20601 - Medical engineering
Návaznosti výsledku
Projekt
<a href="/cs/project/GX19-26127X" target="_blank" >GX19-26127X: Robotický nano-lékárník: Výrobní procesy budoucnosti pro personalisovaná terapeutika</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2023
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
International Journal of Pharmaceutics
ISSN
0378-5173
e-ISSN
1873-3476
Svazek periodika
636
Číslo periodika v rámci svazku
122838
Stát vydavatele periodika
NL - Nizozemsko
Počet stran výsledku
11
Strana od-do
—
Kód UT WoS článku
000959522200001
EID výsledku v databázi Scopus
2-s2.0-85150300624